Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)

In this study of 18,472 patients testing positive for COVID-19 found no significant association between ACEI and/or ARB use with COVID-19 test positivity (overlap propensity score-weighted OR 0.97, 95% CI 0.81-1.15).

SPS commentary:

Authors state that these clinical data support current professional society guidelines to not discontinue ACEIs or ARBs in the setting of the COVID-19 pandemic.


A related editorial highlights that these results provide important clinical data to support current treatment recommendations regarding use in ACEIs/ARBs in the current COVID-19 pandemic. Despite the limitations of observational data and the unique challenges of conducting studies in the setting of COVID-19, the primary analysis is consistent with good observational research.


JAMA Cardiology

Resource links: